HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grajewski, R. S. Articles by Caspi, R. R. Search for Related Content PubMed PubMed Citation Articles by Grajewski, R. S. Articles by Caspi, R. R.

Activation of Invariant NKT Cells Ameliorates Experimental Ocular Autoimmunity by A Mechanism Involving Innate IFN- Production and Dampening of the Adaptive Th1 and Th17 Responses¹

Rafael S. Grajewski^2,3,*, Anna M. Hansen^2,*, Rajeev K. Agarwal^4,*, Mitchell Kronenberg, Stephane Sidobre, Shao Bo Su^5,*, Phyllis B. Silver^*, Moriya Tsuji, Richard W. Franck, Anne P. Lawton, Chi-Chao Chan^* and Rachel R. Caspi^6,*

^* Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892; La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037; Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016; and Hunter College of the City University of New York, New York, NY 10021

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Invariant NKT cells (iNKT cells) have been reported to play a role not only in innate immunity but also to regulate several models of autoimmunity. Furthermore, iNKT cells are necessary for the generation of the prototypic eye-related immune regulatory phenomenon, anterior chamber associated immune deviation (ACAID). In this study, we explore the role of iNKT cells in regulation of autoimmunity to retina, using a model of experimental autoimmune uveitis (EAU) in mice immunized with a uveitogenic regimen of the retinal Ag, interphotoreceptor retinoid-binding protein. Natural strain-specific variation in iNKT number or induced genetic deficiencies in iNKT did not alter baseline susceptibility to EAU. However, iNKT function seemed to correlate with susceptibility and its pharmacological enhancement in vivo by treatment with iNKT TCR ligands at the time of uveitogenic immunization reproducibly ameliorated disease scores. Use of different iNKT TCR ligands revealed dependence on the elicited cytokine profile. Surprisingly, superior protection against EAU was achieved with -C-GalCer, which induces a strong IFN- but only a weak IL-4 production by iNKT cells, in contrast to the ligands -GalCer (both IFN- and IL-4) and OCH (primarily IL-4). The protective effect of -C-GalCer was associated with a reduction of adaptive Ag-specific IFN- and IL-17 production and was negated by systemic neutralization of IFN-. These data suggest that pharmacological activation of iNKT cells protects from EAU at least in part by a mechanism involving innate production of IFN- and a consequent dampening of the Th1 as well as the Th17 effector responses.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Invariant NKT cells (iNKT)⁷ are considered to represent an innate subset of T cells. iNKT cells have a semi-invariant V14-J18 TCR repertoire specific for lipid Ags that are presented on the MHC class I-like CD1d molecule. -Galactosylceramide (-GalCer), a synthetic glycolipid derived from marine sponges, is a well known iNKT TCR ligand (1). Recently, natural ligands of iNKT TCR have been described, such as -glucuronosylceramide and glycosphingolipids from Sphingomonadaceae (2, 3, 4), that resemble cell wall constituents of some Gram-negative bacteria, supporting an innate role of iNKT cells in some infectious diseases. Other studies also revealed regulatory and protective properties in various models of autoimmunity such as experimental autoimmune encephalomyelitis (EAE) and type-1 diabetes (reviewed in Ref. 1). Most of these studies used synthetic ligands for iNKT cell activation and therapeutic regimen.

Upon ligation of their invariant TCR with -GalCer, iNKT cells rapidly produce large amounts of cytokines such as IFN- and IL-4 (5). Analogues of -GalCer prepared by total synthesis led to the identification of ligands that induce a cytokine pattern that is more biased toward either a Th1-type (IFN-) or a Th2-type (IL-4) response. An example of the former is -C-GalCer, whereas the latter includes the ligand (2s,3s,4r)-1-O-(-_D-galactopyranosyl)-N-tetracosanoyl-2-amino-1,3,4-nonanetriol) (OCH) (6, 7). Some studies demonstrated altered biological effects of these -GalCer analogues on autoimmunity and cancer that could be ascribed to the cytokine profiles they elicit (6, 7).

Experimental autoimmune uveitis (EAU) induced in animals by immunization with retinal Ags in CFA is a model for human autoimmune uveitis, a disease that accounts for 10–15% of severe visual handicap in the US. EAU is induced by immunization with the same retinal Ags that are recognized by uveitis patients and is dependent on CD4⁺ Th1 and Th17 effector cells (8, 9). EAU in mice is induced with the interphotoreceptor retinoid-binding protein (IRBP) or with its pathogenic fragments emulsified in CFA (8).

The relationship between NKT cells and eye-related immune responses is not well understood. Although iNKT cells have been shown to play an important role in the eye-related regulatory phenomenon known as anterior chamber-associated immune deviation (ACAID) (10, 11), the possible role of iNKT cells in regulation of EAU has not been established. In the present study, we examine the role of iNKT cells and the effects of the iNKT cell ligands on EAU. Our data show that although natural strain-specific variations or genetically induced lack of iNKT cells do not seem to affect the threshold of susceptibility to EAU, iNKT function seemed to correlate with susceptibility. Importantly, a pharmacological enhancement of these cells using glycolipid iNKT cell ligands was able to inhibit induction of disease. This appeared to be due at least in part to iNKT-produced IFN- and a consequent dampening of the adaptive Th1 and Th17 pathogenic effector responses.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Animals

B10.RIII, B10.A, C57BL/6, DBA/2, AKR, and BALB/c mice (wild-type (WT) and CD1d-knockout (KO)) were purchased from The Jackson Laboratory. All experiments were approved by the National Eye Institute Animal Care and Use Committee. Animal care and use conformed to Institutional guidelines and to the Association for Research in Vision and Ophthalmology guidelines on the use of animals in ophthalmic and vision research.

Ags and reagents

Bovine IRBP was purified as described (12, 13). CFA was purchased from Difco and was supplemented with additional Mycobacterium tuberculosis H37RA to 2.5 mg/ml. Purified derivative of tuberculin (PPD) was purchased from the Statens Seruminstitut. -GalCer (KRN7000) was provided by the Kirin Brewery (14). -C-GalCer was synthesized as described previously (6). OCH was synthesized by Drs. Chi-Huey Wong and Douglas Wu of the Scripps Research Institute, La Jolla, CA. Neutralizing anti-IFN- Abs (clone R4-6A2) were obtained from the Biological Resources Branch, National Cancer Institute.

Isolation of lymphoid cells from liver

Livers were perfused in situ through the hepatic portal vein with PBS and minced into small pieces in PBS with 2% FCS and 0.02% sodium azide (PBS/FCS/Az). The tissue was then pressed though a 200-gauge mesh and cells were suspended in cold (4°C) PBS/FCS/Az. Cells were washed twice (500 g for 7 min). The pelleted cells were resuspended in 37.5% isotonic percoll at room temperature (25 ml per liver) and spun at 680g for 12 min. The cell pellet made up of lymphocytes and erythrocytes was collected, washed once in PBS/FCS/Az, and erythrocytes were lysed with 2 ml red cell lysis buffer (Sigma-Aldrich) for 4 min. Cells were then recovered by centrifugation through a layer of FBS, resuspended in PBS/FCS/Az, filtered through 100-µm mesh, counted, and prepared for immunophenotyping by flow cytometry.

Immunization, EAU induction, and EAU scoring

C57BL/6 and BALB/c mice were immunized with 150 µg of bovine IRBP emulsified in CFA supplemented with Mycobacterium tuberculosis, strain H37RA from Difco to 2.5 mg/ml. Clinical disease was evaluated by fundus examination in a masked fashion and was scored on a scale from 0 (no inflammation) to 4 (complete destruction of the retina) in half-point increments, as described previously (8). Eyes were harvested for histopathology 21 days after immunization. Disease was scored by an ophthalmic pathologist (C.-C. Chan) in a masked fashion as described previously (8).

-GalCer and other treatments

Unless otherwise noted, 5 µg of either -GalCer, -C-GalCer, or OCH were added to and emulsified with the uveitogenic Ag preparation (IRBP/CFA 1:1 v/v). The emulsion was injected s.c., divided into three doses (both thighs and base of tail). Systemic IFN- neutralization was achieved by treatment with monoclonal anti-IFN- Ab, 150 µg/mouse injected i.p. on days –2, 0, and 2).

Determination of immunological responses

Cytokine production to -GalCer analogues in culture was examined on splenocytes obtained from naive mice. Cell suspensions of 2.5 x 10⁶ cells/ml were incubated with 100 ng/ml of the stimulant and supernatants were collected after 48 h. Cytokine production in vivo to -GalCer analogues was measured in sera collected at the indicated time points after i.p. injection of 5 µg of the analog. For determination of Ag-specific cytokine production and proliferation, spleens and lymph nodes draining the site of immunization (inguinal and iliac) were collected on day 21 and were pooled within each group. Proliferation to the indicated doses of Ag was assayed by [³H]thymidine uptake during the last 16 h of a 72-h culture on triplicate cultures of 0.2 ml, as described (15). Cytokine responses were determined using the Pierce Chemical multiplex SearchLight Arrays technology (Ref. 16 and http://www.endogen.com/services).

Flow cytometry

iNKT cells were enumerated by flow cytometry after exclusion of dead cells by DNA staining with 7-amino-actinomycin D. Cells were reacted with PE-labeled CD1d/-GalCer tetramers, allophycocyanin-labeled β-TCR, and FITC-labeled anti-CD4 Abs. β-TCR-positive cells were gated, and the percentage of -GalCer-positive cells (either CD4⁺ or CD4^–) was determined by counting of 1 x 10⁵ viable β-TCR-positive cells. Multiplication of percentages by absolute numbers of lymphocytes that were isolated from each organ (β counter) resulted in the total iNKT numbers shown in Fig. 1.

View larger version (43K): [in this window] [in a new window]   FIGURE 1. Total iNKT cell numbers and percentages of CD4+ NKT cells seem unrelated to susceptibility to EAU. Six different mouse strains (six mice per strain, 8 wk of age) were immunized with 150 µg IRBP in CFA and an additional i.p. injection of 0.3 µg pertussis toxin. B10.RIII mice were immunized with 10 µg IRBP without additional pertussis toxin. a, Schematic representation of typical strain-specific disease scores and representative histopathology (inset), based on established data. Lymphocytes from naive livers, thymuses and spleens were isolated on a density gradient, and iNKT cell numbers were determined by flow cytometry using labeled CD1d/-GalCer tetramers, anti-CD4, and anti-β-TCR Abs as described in Materials and Methods. b, Average of isolated iNKT cell numbers in thymus, lymph node, and spleen, expressed as a total cell number collected from each mouse. c, Average of isolated NKT cell numbers in thymus, lymph node and spleen, expressed as a percentage of the total cell number collected from each mouse. d, Proportion of CD4+ iNKT cells expressed as a percentage of total iNKT cells. The data are pooled from two identical experiments of three mice each (total six individual animals per point).

All experiments were performed at least twice and results were highly reproducible. Figures show data from representative or from pooled experiments, as specified. EAU severity is represented by fundoscopy scores determined on days 19–21. All fundoscopy scores were confirmed by histopathology. Where appropriate, statistical analysis of EAU severity was performed using the Snedecor and Cochran z test for linear trend in proportions (17). This is a nonparametric, frequency-based test that takes into account both disease severity and incidence. Probability values of <0.05 were considered to be significant. Values determined to be significantly different from controls are marked with an asterisk in the figures.

	Results

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
iNKT cytokine profile, but not their number, may correlate with susceptibility to EAU

EAU is a disease model where susceptibility varies considerably among different mouse strains. The strain with the highest known susceptibility is B10.RIII. B10.A is another susceptible strain that can develop high disease scores, but, unlike the B10.RIII strain, it requires administration of pertussis toxin at the time of immunization to develop EAU, as do all other susceptible strains. C57BL/6 and DBA/2 mice have mild to moderate susceptibility, and AKR as well as BALB/c mice are resistant to disease. We asked the question whether susceptibility to disease in a series of EAU-characterized mouse strains correlated with their numbers of iNKT cells. Fig. 1a shows a schematic representation of typical EAU scores for six mouse strains, summarizing previously reported findings (18, 19, 20). Representative pictures of severe, mild and no disease are shown in the inset.

Most of the iNKT cells in the body are concentrated in the thymus, liver and spleen. We enumerated invariant TCR-bearing NKT cells in these three organs in the different mouse strains using flow cytometry, by binding of PE-labeled CD1d/-GalCer-tetramers. Although there were strain-specific differences in iNKT cell numbers and variations in their content in the different organs, there was no correlation with strain-specific differences in disease susceptibility (Fig. 1, b and c). In addition, a low iNKT number in one organ (e.g., thymus B10.A and spleen AKR) tended to be counterbalanced by a higher number in another organ (e.g., liver of B10.A and AKR) in some strains. Consequently, the total number of iNKT cells was often similar between strains with different EAU susceptibilities (Fig. 1b).

We next examined the percent of CD4⁺ iNKT cells of the total iNKT cells, as this subset plays a role in the eye-specific regulatory phenomenon known as ACAID (11, 21). CD4⁺ iNKT cells were enumerated by double staining for CD4 and for the invariant TCR using CD1d/-GalCer tetramers. The data revealed that the differences in CD4⁺ iNKT cells between the strains were even less pronounced than total iNKT numbers and did not correlate with disease susceptibility (Fig. 1d).

Lastly, we selected three strains that were either resistant, moderately susceptible, or highly susceptible to EAU (BALB/c, C57BL/6, and B10RIII, respectively) and tested their iNKT cells in vitro using two different ligands, -GalCer and OCH, each known to elicit differing cytokine profiles (4, 22). Single-cell suspensions were made from whole spleens and were stimulated with the indicated ligands for 48 h. Analysis of culture supernatants revealed that iNKT cells in resistant BALB/c mice produce significantly higher levels of IFN-, IL-4, and IL-2, irrespective of the ligand used for stimulation (Fig. 2). Interestingly, the opposite was the case with IL-17, with the highest levels detected in supernatant of B10RIII splenocytes. iNKT cells have recently been identified as a source of innate IL-17 (23), although the significance of this response for autoimmune disease is yet to be defined. No interstrain differences were found in other cytokines examined, such as IL-10, IL-13, and IL-5 (not shown).

View larger version (34K): [in this window] [in a new window]   FIGURE 2. Functional differences are present in iNKT cells from susceptible, compared with resistant, strains. Splenocytes from BALB/c, C57BL/6, and B10RIII mice were isolated and cultured in HL-1 media containing 1% normal mouse serum and were left either unstimulated or were treated with 100 ng/ml of either -GalCer or OCH, as indicated in the figure. Cell supernatants were collected after 48 h and cytokines were analyzed by Pierce Searchlight Technology. Data are representative of two experiments with three individual mice in each group. Supernatants were pooled before analysis.

If iNKT cells had a role in raising the threshold of susceptibility to EAU, we would expect that iNKT deficiency would result in more severe disease. However, mice deficient in CD1d (lacking CD1d-dependent NKT cells) (24) did not show enhanced EAU susceptibility compared with their WT counterparts (Fig. 3). The time of onset as well as the course of disease as determined by periodic fundus examinations were also not affected (data not shown). Mice deficient in CD1d on the resistant BALB/c background remained resistant (Fig. 3). These data are consistent with observations made by others in the EAE model (25, 26, 27).

View larger version (13K): [in this window] [in a new window]   FIGURE 3. Lack of NKT cells does not seem to alter the disease course or the susceptibility to EAU. An EAU-susceptible (C57BL/6) and resistant strain (BALB/c) was immunized as described in Fig. 1a. Likewise NKT-deficient strains on these genetic backgrounds were immunized, and EAU scores were compared with the WT mice. EAU scores of C57BL/6 WT and J18-KO mice. Representative experiment of two showing the same pattern (data were not pooled due to inter-experiment variation in disease severity). Positive mice of total are indicated within each bar.

Activation of iNKT cells ameliorates EAU but analogues of -GalCer differ in their efficacy

We next examined whether functional triggering of iNKT cells using invariant TCR ligands can affect EAU. Five micrograms of -GalCer incorporated into the IRBP/CFA emulsion ameliorated EAU severity and incidence in C57BL/6 mice (Fig. 4a). To examine the effect of -GalCer analogues, mice were similarly treated with -C-GalCer and OCH. The data showed that OCH protected no better than -GalCer, whereas -C-GalCer was the most effective (Fig. 4b).

View larger version (19K): [in this window] [in a new window]   FIGURE 4. Effect of iNKT cell activation on EAU. a, Activation of NKT cells ameliorates EAU. C57BL/6 WT mice were immunized with IRBP as described in Fig. 1a with (black column) or without (white column) 5 µg of the synthetic iNKT cell ligand -GalCer. EAU scores on day 19 after immunization are shown (p < 0.005). b, Analogues of -GalCer differ in their ability to ameliorate EAU. C57BL/6 WT mice were immunized as described in Fig. 1a without (white column) or with 5 µg of the synthetic iNKT cell ligand -GalCer (black column, p vs control <0.09) or -C-GalCer (gray column, p vs control <0.02) or OCH (dark gray column, p. vs control <0.22). Data combined from three experiments.

View larger version (15K): [in this window] [in a new window]   FIGURE 5. Differing cytokine profiles are elicited by -GalCer analogues in vivo. C57BL/6 WT mice were injected i.p. with 5 µg of either -GalCer, -C-GalCer, or OCH. Serum was collected from three mice at the indicated times (hours after injection). The assay was performed on pooled serum samples; therefore, error bars could not be generated.

Protective effect of iNKT cells in EAU seems to require innate IFN- and is associated with reduced adaptive IFN- and IL-17 responses

As we have previously observed that systemically produced IFN- can have a protective role in EAU (19, 28, 29), we decided to examine whether the enhanced protective effect of -C-GalCer compared with the other analogues was due to its ability to induce enhanced production of IFN- by iNKT cells. We therefore injected mice immunized for EAU in the presence of -C-GalCer with neutralizing Abs to IFN- at the time of immunization, when innate production of IFN- induced by -C-GalCer would be occurring (according to the timeline established in Fig. 5). EAU and adaptive IFN- and IL-17, representing pathogenic effector Th1 and Th17 cell responses, were examined. Mice protected from disease with -C-GalCer had strongly reduced adaptive IFN- and IL-17 responses (Fig. 6). Neutralization of IFN- at the time of immunization restored EAU scores in -C-GalCer-treated mice, but had no effect on disease progression in the control group, demonstrating a specific requirement for IFN- in the protection. In addition, subsequent Ag-specific production of IFN- and IL-17 was restored (Fig. 6, b and c), supporting the notion that innate production of IFN- elicited by -C-GalCer had a role in the protection and in inhibition of adaptive responses induced by this analog.

View larger version (16K): [in this window] [in a new window]   FIGURE 6. Protective effect of iNKT cells in EAU seems to require innate IFN- and is associated with reduced adaptive IFN- and IL-17 responses. C57BL/6 WT mice were immunized as described in Fig. 1a with or without additional 5 µg of the iNKT cell ligand -C-GalCer in the emulsion. Mice were injected with anti-IFN- or isotype on days–2, 0 and 2 relative to immunization. a, EAU scores on day 19 after immunization. Positive out of total mice are shown within the bars. Only the -C-GalCer treated group is significantly different from control (p < 0.028); (b) IFN- and (c) IL-17 titers in pooled supernatants of splenocytes from the mice in a obtained on day 21 after immunization and cultured for 48 h with 30 µg IRBP. Note that due to the fact that the assay was conducted on pooled supernatants the results represent an average of the group but no error bars could be generated. Cytokine levels were determined using Pierce Searchlight Technology. Control cultures were set up without IRBP (IFN- <200 pg/ml, IL-17 < 15 pg/ml). Shown is a representative experiment of two.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

The group of Stein-Streilein (10, 11, 21) demonstrated that iNKT cells have a central role in ACAID, a prototypic regulatory phenomenon elicited by injection of Ag into the anterior chamber of the eye and its transport by eye-derived APC to the spleen. iNKT cells are recruited into the spleen via a mechanism involving MIP-2 and participate in priming the adaptive T regulatory cells typically associated with ACAID. Although prior elicitation of ACAID to IRBP can inhibit a subsequent episode of EAU (32), it is unlikely that the protection from EAU by iNKT that we observe here bears a relationship to their role in ACAID. In ACAID, the eliciting Ag originates from the eye, which has to be perturbed (injected with Ag) in order for this phenomenon to be observed, and iNKT activation, if any, occurs without additional manipulation. In contrast, in our study, pharmacological activation of iNKT cells is needed and is applied when the eye is still intact. Thus, it is conceivable that iNKT cells may regulate ocular immune responses at more than one level.

Studies in the models of experimental arthritis, NOD diabetes, and EAE (reviewed in Ref. 22) had indicated that activation of iNKT by OCH is more effective than by -GalCer, which was attributed to its induction of IL-4 and Th2 skewing. We were therefore surprised to find that OCH was not more effective than -GalCer in protecting from EAU, and that the most efficient protection followed administration of -C-GalCer, which induces an IFN- dominated iNKT cytokine response. Thus, effectiveness of protection paralleled the innate IFN- inducing ability of the invariant TCR ligand. The protection was accompanied by reduction in the IRBP-specific adaptive Th1 and Th17 pathogenic effector responses, as judged by production of their respective hallmark cytokines IFN- and IL-17 to in vitro recall with IRBP. The functional role of IFN- in the protective and regulatory effects of iNKT are strongly supported by direct evidence showing that neutralization of innate IFN- reversed the protective effect of -C-GalCer and restored the subsequent proinflammatory cytokine production of the adaptive response. This is not to say that the mechanism of protection is the same for all the three analogues. Our data do not negate the possibility that protection from EAU by OCH and by -GalCer could involve IL-4, as was previously demonstrated in several other autoimmune disease models (22).

Our data are in line with some previous reports, which revealed that protection from autoimmune disease by iNKT may not always involve IL-4 and Th2 skewing. Studies by Lehuen and her colleagues (33, 34) demonstrated that even in the absence of IL-4, iNKT cells can control EAE and experimental type 1 diabetes. This was associated with a decrease in Th1-associated pathogenic autoimmune responses without inducing Th2 responses and was due at least in part to induction of anergy in the autoreactive T cells (35). Such a mechanism could also be involved in the prevention of EAU observed here. Although these studies did not directly implicate IFN- in these effects, participation of IFN- (rather than IL-4) in protection from EAE was suggested by Furlan et al. (27).

It should be noted that high systemic levels of IFN- early or late in the disease can be protective, but likely by different mechanisms. Initial production of IFN- would be mostly from NKT and NK cells, whereas later in disease Ag-specific Th1 cells are a major source of IFN-. We previously showed that early up-regulation of IFN- by injections of IL-12 inhibits development of EAU and associated immunological responses by aborting priming, through a process that involves induction of NO and apoptosis (29). The innate IFN- produced by -C-GalCer-triggered NKT cells may well work in a similar fashion. In contrast, protective effects of IFN- later in the disease appear to be due to its role in elimination of spent effector cells by activation-induced cell death (36, 37). Thus, neutralization of systemic IFN- at that stage also enhances disease (19), although at that point it is not possible to distinguish between effects of IFN- produced by Ag-specific T cells and iNKT cells.

In summary, we have demonstrated that iNKT cells can actively participate in regulating the autoimmune response to immunologically privileged retinal Ags. This apparently occurs at a different level than their role in induction of ACAID. The mechanism involves the induction of innate IFN- production through ligation of the invariant TCR and results in inhibited development of adaptive Th1 and Th17 responses that represent pathogenic effector mechanisms in uveitis.

	Acknowledgments

 
We thank Dr. S. Yamano of the Kirin Brewery, Tokyo, Japan for providing -GalCer (KRN7000) and Drs. Chi-Huey Wong and Douglas Wu of the Scripps Research Institute, La Jolla, CA for synthesizing the OCH used in this study.

	Disclosures

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
The authors have no financial conflict of interest.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by National Institutes of Health Intramural funding.

² R.S.G. and A.M.H. contributed equally to this study.

³ Current address: Würzburg University, University Eye Hospital, Josef-Schneider-Strasse 11, 97080 Würzburg, Germany.

⁴ Current address: Organ Systems Branch, Office of Centers, Training and Resources, Office of the Director, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Suite 7006, Rockville, MD 20852.

⁵ Current address: Institute of Inflammation and Immune Diseases, Shantou University Medical College, 22 Xin Ling Road, Shantou City, 515041, People’s Republic of China.

⁶ Address correspondence and reprint requests to Dr. Rachel R. Caspi, Laboratory of Immunology, National Eye Institute, National Institutes of Health, 10 Center Drive, 10/10n222, Bethesda, MD 20892-1857. E-mail address: rcaspi{at}helix.nih.gov

⁷ Abbreviations used in this paper: iNKT, invariant NKT cell; EAU, experimental autoimmune uveitis; IRBP, interphotoreceptor retinoid-binding protein; -GalCer, -galactosylceramide; OCH, (2s,3s,4r)-1-O-(-D-galactopyranosyl)-N-tetracosanoyl-2-amino-1,3,4-nonanetriol); ACAID, anterior chamber-associated immune deviation; WT, wild type; KO, knockout; EAE, experimental autoimmune encephalomyelitis.

Received for publication April 16, 2007. Accepted for publication July 29, 2008.

	References

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 

1. Wilson, S. B., T. L. Delovitch. 2003. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol. 3: 211-222. [Medline]
2. Rowe, N. J., J. Tunstall, L. Galbraith, S. G. Wilkinson. 2000. Lipid composition and taxonomy of Pseudomonas echinoides: transfer to the genus Sphingomonas. Microbiology 146: 3007-3012. [Abstract/Free Full Text]
3. Kinjo, Y., D. Wu, G. Kim, G. W. Xing, M. A. Poles, D. D. Ho, M. Tsuji, K. Kawahara, C. H. Wong, M. Kronenberg. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434: 520-525. [Medline]
4. Tsuji, M.. 2006. Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cell Mol. Life Sci. 63: 1889-1898. [Medline]
5. Tupin, E., M. Kronenberg. 2006. Activation of natural killer T cells by glycolipids. Methods Enzymol. 417: 185-201. [Medline]
6. Schmieg, J., G. Yang, R. W. Franck, M. Tsuji. 2003. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand -galactosylceramide. J. Exp. Med. 198: 1631-1641. [Abstract/Free Full Text]
7. Yamamura, T., K. Miyamoto, Z. Illes, E. Pal, M. Araki, S. Miyake. 2004. NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease. Curr. Top. Med. Chem. 4: 561-567. [Medline]
8. Agarwal, R. K., R. R. Caspi. 2004. Rodent models of experimental autoimmune uveitis. Methods Mol. Med. 102: 395-420. [Medline]
9. Luger, D., P. B. Silver, J. Tang, D. Cua, Z. Chen, Y. Iwakura, E. P. Bowman, N. M. Sgambellone, C. C. Chan, R. R. Caspi. 2008. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med. 205: 799-810. [Abstract/Free Full Text]
10. Faunce, D. E., K. H. Sonoda, J. Stein-Streilein. 2001. MIP-2 recruits NKT cells to the spleen during tolerance induction. J. Immunol. 166: 313-321. [Abstract/Free Full Text]
11. Sonoda, K. H., M. Exley, S. Snapper, S. P. Balk, J. Stein-Streilein. 1999. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J. Exp. Med. 190: 1215-1226. [Abstract/Free Full Text]
12. Pepperberg, D. R., T. L. Okajima, B. Wiggert, H. Ripps, R. K. Crouch, G. J. Chader. 1993. Interphotoreceptor retinoid-binding protein (IRBP): molecular biology and physiological role in the visual cycle of rhodopsin. Mol. Neurobiol. 7: 61-85. [Medline]
13. Pepperberg, D. R., T. L. Okajima, H. Ripps, G. J. Chader, B. Wiggert. 1991. Functional properties of interphotoreceptor retinoid-binding protein. Photochem. Photobiol. 54: 1057-1060. [Medline]
14. Sakai, T., O. V. Naidenko, H. Iijima, M. Kronenberg, Y. Koezuka. 1999. Syntheses of biotinylated -galactosylceramides and their effects on the immune system and CD1 molecules. J. Med. Chem. 42: 1836-1841. [Medline]
15. Silver, P. B., L. V. Rizzo, C. C. Chan, L. A. Donoso, B. Wiggert, R. R. Caspi. 1995. Identification of a major pathogenic epitope in the human IRBP molecule recognized by mice of the H-2r haplotype. Invest. Ophthalmol. Visual Sci. 36: 946-954. [Abstract/Free Full Text]
16. Moody, M. D., S. W. Van Arsdell, K. P. Murphy, S. F. Orencole, C. Burns. 2001. Array-based ELISAs for high-throughput analysis of human cytokines. BioTechniques 31: 186-190. 192–184. [Medline]
17. Snedecor, G. W., W. G. Cochran. 1967. Statistical Methods Iowa State University Press, Iowa.
18. Caspi, R. R., B. G. Grubbs, C. C. Chan, G. J. Chader, B. Wiggert. 1992. Genetic control of susceptibility to experimental autoimmune uveoretinitis in the mouse model: concomitant regulation by MHC and non-MHC genes. J. Immunol. 148: 2384-2389. [Abstract]
19. Caspi, R. R., C. C. Chan, B. G. Grubbs, P. B. Silver, B. Wiggert, C. F. Parsa, S. Bahmanyar, A. Billiau, H. Heremans. 1994. Endogenous systemic IFN- has a protective role against ocular autoimmunity in mice. J. Immunol. 152: 890-899. [Abstract]
20. Sun, B., L. V. Rizzo, S. H. Sun, C. C. Chan, B. Wiggert, R. L. Wilder, R. R. Caspi. 1997. Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T helper-1-like or a T helper-2-like response. J. Immunol. 159: 1004-1011. [Abstract]
21. Nakamura, T., K. H. Sonoda, D. E. Faunce, J. Gumperz, T. Yamamura, S. Miyake, J. Stein-Streilein. 2003. CD4⁺ NKT cells, but not conventional CD4⁺ T cells, are required to generate efferent CD8⁺ T regulatory cells following antigen inoculation in an immune-privileged site. J. Immunol. 171: 1266-1271. [Abstract/Free Full Text]
22. Miyake, S., T. Yamamura. 2005. Therapeutic potential of glycolipid ligands for natural killer (NK) T cells in the suppression of autoimmune diseases. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 315-322. [Medline]
23. Rachitskaya, A. V., A. M. Hansen, R. Horai, Z. Li, R. Villasmil, D. Luger, R. B. Nussenblatt, R. R. Caspi. 2008. Cutting edge: NKT cells constitutively express IL-23 receptor and RORt and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J. Immunol. 180: 5167-5171. [Abstract/Free Full Text]
24. Hong, S., D. C. Scherer, N. Singh, S. K. Mendiratta, I. Serizawa, Y. Koezuka, L. Van Kaer. 1999. Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice. Immunol. Rev. 169: 31-44. [Medline]
25. Singh, A. K., M. T. Wilson, S. Hong, D. Olivares-Villagomez, C. Du, A. K. Stanic, S. Joyce, S. Sriram, Y. Koezuka, L. Van Kaer. 2001. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194: 1801-1811. [Abstract/Free Full Text]
26. Jahng, A. W., I. Maricic, B. Pedersen, N. Burdin, O. Naidenko, M. Kronenberg, Y. Koezuka, V. Kumar. 2001. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194: 1789-1799. [Abstract/Free Full Text]
27. Furlan, R., A. Bergami, D. Cantarella, E. Brambilla, M. Taniguchi, P. Dellabona, G. Casorati, G. Martino. 2003. Activation of invariant NKT cells by GalCer administration protects mice from MOG35–55-induced EAE: critical roles for administration route and IFN-. Eur. J. Immunol. 33: 1830-1838. [Medline]
28. Jones, L. S., L. V. Rizzo, R. K. Agarwal, T. K. Tarrant, C. C. Chan, B. Wiggert, R. R. Caspi. 1997. IFN--deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J. Immunol. 158: 5997-6005. [Abstract]
29. Tarrant, T. K., P. B. Silver, J. L. Wahlsten, L. V. Rizzo, C. C. Chan, B. Wiggert, R. R. Caspi. 1999. Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon , nitric oxide, and apoptosis. J. Exp. Med. 189: 219-230. [Abstract/Free Full Text]
30. Avichezer, D., R. S. Grajewski, C. C. Chan, M. J. Mattapallil, P. B. Silver, J. A. Raber, G. I. Liou, B. Wiggert, G. M. Lewis, L. A. Donoso, R. R. Caspi. 2003. An immunologically privileged retinal antigen elicits tolerance: major role for central selection mechanisms. J. Exp. Med. 198: 1665-1676. [Abstract/Free Full Text]
31. Grajewski, R. S., P. B. Silver, R. K. Agarwal, S. B. Su, C. C. Chan, G. I. Liou, R. R. Caspi. 2006. Endogenous IRBP can be dispensable for generation of natural CD4⁺CD25⁺ regulatory T cells that protect from IRBP-induced retinal autoimmunity. J. Exp. Med. 203: 851-856. [Abstract/Free Full Text]
32. Hara, Y., R. R. Caspi, B. Wiggert, C. C. Chan, G. A. Wilbanks, J. W. Streilein. 1992. Suppression of experimental autoimmune uveitis in mice by induction of anterior chamber-associated immune deviation with interphotoreceptor retinoid-binding protein. J. Immunol. 148: 1685-1692. [Abstract]
33. Mars, L. T., V. Laloux, K. Goude, S. Desbois, A. Saoudi, L. Van Kaer, H. Lassmann, A. Herbelin, A. Lehuen, R. S. Liblau. 2002. Cutting edge: V14-J 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J. Immunol. 168: 6007-6011. [Abstract/Free Full Text]
34. Novak, J., L. Beaudoin, T. Griseri, A. Lehuen. 2005. Inhibition of T cell differentiation into effectors by NKT cells requires cell contacts. J. Immunol. 174: 1954-1961. [Abstract/Free Full Text]
35. Beaudoin, L., V. Laloux, J. Novak, B. Lucas, A. Lehuen. 2002. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic β cells. Immunity 17: 725-736. [Medline]
36. Chu, C. Q., S. Wittmer, D. K. Dalton. 2000. Failure to suppress the expansion of the activated CD4 T cell population in interferon -deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J. Exp. Med. 192: 123-128. [Abstract/Free Full Text]
37. Dalton, D. K., L. Haynes, C. Q. Chu, S. L. Swain, S. Wittmer. 2000. Interferon eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J. Exp. Med. 192: 117-122. [Abstract/Free Full Text]

This article has been cited by other articles:

				Z. Cao, Y. Yuan, G. Jeyabalan, Q. Du, A. Tsung, D. A. Geller, and T. R. Billiar Preactivation of NKT cells with {alpha}-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor Am J Physiol Gastrointest Liver Physiol, August 1, 2009; 297(2): G249 - G258. [Abstract] [Full Text] [PDF]

				L. T. Mars, L. Araujo, P. Kerschen, S. Diem, E. Bourgeois, L. P. Van, N. Carrie, M. Dy, R. S. Liblau, and A. Herbelin Invariant NKT cells inhibit development of the Th17 lineage PNAS, April 14, 2009; 106(15): 6238 - 6243. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grajewski, R. S. Articles by Caspi, R. R. Search for Related Content PubMed PubMed Citation Articles by Grajewski, R. S. Articles by Caspi, R. R.